Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Editorial Comment to “Primary Resistance to Immune Checkpoint Inhibitor Combination Therapy in Metastatic Renal Cell Carcinoma: Focus on Nivolumab Plus Ipilimumab”. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1111/iju.70597
10.1111/iju.70597 · External reference
10.1016/j.annonc.2026.02.017
10.1016/j.annonc.2026.02.017 · External reference
10.1136/jitc‐2021‐004316
10.1136/jitc‐2021‐004316 · External reference
10.1016/s1470‐2045(22)00128‐0
10.1016/s1470‐2045(22)00128‐0 · External reference
10.1016/j.annonc.2026.02.011
10.1016/j.annonc.2026.02.011 · External reference
